Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter. Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients. Read More
The post Zelda Therapeutics makes significant progress in medicinal cannabis research programs appeared first on Dagga Magazine.